HOST: CO- HOSTS: SHERATON WALL CENTRE HOTEL 1088 BURRARD STREET Vancouver, BC, Canada April 22 to 25, 2012 CO- SPONSORS: MAJOR INDUSTRY SPONSORS:

Transcription

1 HOST: CO- HOSTS: CO- SPONSORS: SHERATON WALL CENTRE HOTEL 1088 BURRARD STREET Vancouver, BC, Canada April 22 to 25, 2012 OFFICE OF THE US GLOBAL AIDS COORDINATOR-THE UNITED STATES PRESIDENT S EMERGENCY PLAN FOR AIDS RELIEF LOCAL ACADEMIC PARTNERS: MAJOR INDUSTRY SPONSORS: INDUSTRY SUPPORTERS:

2 2 nd International HIV Workshop on Treatment as Prevention Sheraton Wall Centre Hotel 1088 Burrard Street Vancouver, BC, Canada April 22-25, 2012 April 22 th Day 1 (Opening) 15:00-17:00 Registration opens as early as 3:00 pm (Pavilion Foyer) 17:00 Opening Session (Pavilion Ballroom) 17:00-17:05 Welcome and Message from the Chair 17:05-17:25 Keynote Opening Address OGAC perspective on Treatment as Prevention Ambassador Eric Goosby, US Global AIDS Coordinator 17:20-19:00 Round Table: Setting the Stage Moderator: Jack Whitescarver (Office of AIDS Research) Panelists: 1) The state of the science Carl Dieffenbach (on behalf of NIAID) (20 min) 2) UNAIDS perspective Paul de Lay (on behalf of UNAIDS) (20 min) 3) WHO perspective Gottfried Hirnschall (on behalf of WHO) (20 min) 4) Hard to reach populations Nora Volkow (on behalf of NIDA) (20 min) 5) Mapping of TasP clinical trials Francois Dabis (on behalf of ANRS) (20 min) 19:00-19:30 19:30-20:40 Break Round Table: Perspective on TasP implementation Moderator: Elly Katabira

3 19:30-20:10 Panelists: Jim Shelton (15 min) Stephen Lewis (15 min) Moderated Discussion (10 min) 20:10-20:40 Open Microphone Discussion (30 min) 20:40 Day 1 concludes 2

4 April 23 rd Day 2 07:00-08:00 Breakfast Buffet (Pavilion Ballroom Foyer) 08:00-10:00 Review of scientific evidence and policy implications Moderator: Jean- Francois Delfraissy 08:00-09:00 Speakers: 1) HPTN052- Myron Cohen (15 min) 2) San Francisco Perspective - Grant Colfax (15 min) 3) China Perspective - Zunyou Wu (15 min) 4) An MSF Perspective on TasP: ongoing and planned projects in Africa Roger Teck (15 min) 09:00-10:00 Open Microphone Discussion (60 min) 10:00-10:30 10:30-12:00 Break Models, projections and cost- effectiveness analysis Moderator: Geoff Garnett 10:30-11:15 Speakers: 1) Models and projections I - Christophe Fraser (15 min) 2) Models and projections II Brian Williams (15 min) 3) Cost- effectiveness John Blandford (15 min) 11:15-12:00 12:00-13:30 Open Microphone Discussion (45 min) Poster Session & Lunch 13:30-15:30 Emerging insights from models, projections and cost- effectiveness analyses (Part 1) Moderator: Jean- Michel Molina 13:30-14:20 Speakers: 1) Systematic comparison of mathematical models of the potential impact of antiretroviral therapy in HIV incidence in South Africa Jeffrey Eaton (10 min) 3

5 2) Treatment as prevention for HIV in South Africa: different models show consistency in occurrence, but difference in timing of elimination and the overall impact of the intervention Jan Hontelez (10 min) 3) Comparison of universal access versus universal test and treat strategies for South Africa: an epidemiological and economic analysis Bradley Wagner (10 min) 4) Study protocol to evaluate the feasibility and cost- effectiveness of standard treatment vs enhanced service for early treatment initiation in roadside wellness centres attending to mobile populations along a trading corridor across South Africa, Zimbabwe and Zambia Gabriela Gomez (10 min) 5) Earlier initialization of highly active antiretroviral therapy is associated with log term survival and infections averted: findings from a deterministic model of a 10- year Ugandan cohort Fegal Mills (10 min) 14:20-14:35 Open Microphone Discussion (15 min) 14:35-15:30 Emerging insights from models, projections and cost- effectiveness analyses (Part 2) Moderator: Robert Eisinger 14:35-15:15 Speakers: 1) Modelling potential impact of expanding access to antiretroviral therapy and other prevention interventions on the concentrated HIV epidemic in Vietnam Masaya Kato (10 min) 2) Limited contribution to new infections from HIV- infected men who have sex with men on suppressive antiretroviral therapy Ard van Sighem (10 min) 3) The cost of scaling- up antiretroviral treatment: a costing study in 161 representative facilities in Ethiopia, Malawai, Rwanda, South Africa and Zambia Elya Tagar (10 min) 4) Modeling the impact of implementing a test- and- treat strategy within the US Criminal Justice System Viviane Dias Lima (10 min) 15:15-15:30 Open Microphone Discussion (15 min) 4

6 15:30-16:00 Break 16:00-18:15 Global policy (Part 1) Moderator: Bertrand Audoin 16:00-17:00 Speakers: 1) Global Guidelines - Reuben Granich (10 min) 2) When to Start: Investigator Perspective I Wafaa El- Sadr (10 min) 3) When to Start: Investigator Perspective II Diane Havlir (10 min) 4) Ind l v. public health benefit v. both Paul Kasonkomona (10 min) 16:40-17:00 Open Microphone Discussion (20 min) 17:00-18:15 Global policy (Part 2) Moderator: Paul de Lay 17:00-17:45 Speakers: 1) Tx 2.0: Where are we at? Mariangela Simao (15 min) 2) Treatment Optimization Stephen Becker (15 min) 3) Global Fund perspective TBC (15 min) 17:45-18:15 Open Microphone Discussion (30 min) 18:15 Day 2 concludes 19:00 22:00 Dinner Reception (Off site, TBC) 5

7 April 24 th Day 3 07:00-08:00 Breakfast Buffet (Pavilion Ballroom Foyer) 08:00-10:00 Challenges in the design and implementation of STTR initiatives Moderator: Chinazo Cunningham 08:00-09:30 Speakers: 1) PopART, a large cluster- randomised trial of combination prevention strategies: design considerations Christophe Fraser (15 min) 2) Pushing the boundaries of science and practice- MaxART: Maximizing ART for better health and zero new HIV infections in Swaziland Sithembile Dlamini (15 min) 3) Treatment- as- prevention in resource- limited settings: review of strengths, weaknesses, opportunities and threats in the context of Swaziland Charles Azih (15 min) 4) Challenges in the implementing HIV treatment as prevention in China Yan Zhao (15 min) 5) Integrating ART/PMTCT services into Maternal Neonatal & Child Health (MHCH) services to enhance test and treat for pregnant & lactating women (Option B+)- the Malawi experience Zengani Chirwa (15 min) 6) Assessing viral suppression amongst HIV patients accessing care in six cities using US HIV surveillance data for the TLC- Plus (HPTN 065) Study Deborah Donnell (15 min) 09:30-10:00 Open Microphone Discussion (30 min) 10:00-10:30 Break 10:30-12:00 Special Populations (4 orals) Moderator: Yvette Calderon 10:30-11:30 Speakers 1) Changing with the science: Anticipating new standard of care antiretroviral treatment recommendations for discordant couples in a home- based HIV testing cohort in Kenya Peter Cherutich (15 min) 2) The impact of incarceration on linkage to, retention in, and outcomes of care among low- income HIV- positive William Cunningham (15 min) 6

8 11:30-12:00 3) Update and results of opt- out and opt- in HIV testing for women detainees in Cook County Jail, Illinois Lawrence Ouellet (15 min) 4) CARE+ Corrections- Innovative use of technology in jails to support linkage and adherence to HIV care Curt Beckwith (15 min) Open Microphone Discussion (30 min) 12:00-13:30 Poster Session & Lunch 13:30-15:30 STTR Outcomes- initial results (6 orals) Moderator: Jacques Normand 13:30-15:00 Speakers: 1) Seek, test, treat and retain for PWIDs in East Africa: a stepped wedge evaluation of Kenya s needle program- Testing & Linkage to Care for PWIDs (TLC- PWID Kenya) Ann Kurth (15 min) 2) High testing uptake and linkages to HIV treatment through home based HIV counseling and testing and facilitated referral in Kabwohe, Uganda and KwaZulu- Natal (KZN), South Africa Ruanne Barnabas (15 min) 3) Scientific evidence and policy implication of treatment as prevention- China perspective Zunyou Wu (15 min) 4) Provider- initiated HIV testing on hospital admission: first pilot study in Argentina Maria Socias (15 min) 5) TLC- Plus (HPTN 065): design and implementation of a community- fucused HIV prevention study in the United States Wafaa El- Sadr (15 min) 6) Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and HIV new diagnoses- an update on the Treatment as Prevention experience in British Columbia Julio Montaner (15 min) 15:00-15:30 Open Microphone Discussion (30 min) 15:30-16:00 Break 16:00-17:10 Debate Implementation of TasP should await further Efficacy Trials 7

9 Moderator: Mark Harrington 16:00-16:40 Speakers: 1) For Jens Lundgren (15 min) 2) Against Joep Lange (15 min) 3) Rebuttals (5 min each) 16:40-17:10 Open Microphone Discussion (30 min) 17:10 Day 3 concludes 8

10 April 25 th Day 4 07:00-08:00 Breakfast Buffet (Pavilion Ballroom Foyer) 08:00-09:10 Debate TasP should not proceed without Viral Load Monitoring Moderator: Papa Salif Sow 08:00-08:40 Speakers: 1) For Vladimir Novitsky (15 min) 2) Against Jonathan Mermin (15 min) 3) Rebuttals (5 min each) 08:40-09:10 Open Microphone Discussion (30 min) 09:10-10:00 Break 10:00-11:30 Emerging Issues Moderator: Carlos del Rio 10:00-11:00 Speakers: 1) Cascade of care Peter Kilmore (15 min) 2) IAPAC guidelines Melanie Thompson (15 min) 3) Cell phone trials Richard Lester (15 min) 4) Elimination of Paediatric infection and TasP Craig McClure (15 min) 11:00-11:30 11:30-12:30 12:30-13:20 Open Microphone Discussion (30 min) Lunch Impact of antiretroviral therapy on TB control Moderator: Malcolm King 12:30-13:00 Speakers: 1) Stephen Lawn (20 min) 2) Commentary: Haileyesus Getahun (10 min) 9

11 13:00-13:20 Open Microphone Discussion (20 min) 13:20-14:50 Late Breaker Abstracts Session Moderator: Pedro Cahn Speakers: TBD 14:50-15:00 Closing remarks 10